ENETS Abstract Search
CBEZ235Z2401: Randomized Phase II Study of BEZ235 or Everolimus (EVE) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET)
#1196
Introduction: EVE is an mTOR inhibitor (mTORi) approved for the treatment of advanced pNETs. BEZ235, a dual mTOR/PI3K inhibitor, may provide greater PI3K pathway inhibition and enhanced antitumor effects.
Aim(s): To present selected secondary endpoints (safety and overall response rate [ORR; RECIST v1.0]) from this open label, randomized, ph II trial (NCT01628913; cut-off Oct 2014).
Materials and methods: Eligible pts had advanced, well-differentiated pNETs, no prior mTORi, and disease progression within the past year. Randomization (1:1) was stratified by somatostatin analog use and baseline chromogranin A and/or neuron specific enolase levels. Pts received BEZ235 (400 mg bid) or EVE (10 mg qd).
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Libutti S, Garcia-Carbonero R, Wolin E, Custodio A, Yao J,
Keywords: pNET, BEZ235, everolimus,
To read the full abstract, please log into your ENETS Member account.